Comparing the risk of death, major adverse cardiac events, and relapse in bullous pemphigoid patients treated with systemic or topical corticosteroids.
Khalaf KridinKatja BieberArtem VorobyevEva Lotta ModereggerGema HernandezEnno SchmidtRalf J LudwigPublished in: The British journal of dermatology (2024)
Pending validation in prospective studies, where feasible, and despite the heightened risk of relapse, topical corticosteroid treatment may be advantageous compared to systemic corticosteroid treatment due to its significantly lower risk of death.